CO-MUTATIONS AND NON-CANONICAL DRIVER MUTATIONS IDENTIFIED BY NEXT GENERATION SEQUENCING IN MYELOPROLIFERATIVE NEOPLASMS REVEAL SIGNIFICANT OPPORTUNITIES FOR IMPROVED DIAGNOSTIC PRACTICE

EHA Library, Ella Thompson, 293576

CLINICIAL, MORPHOLOGICAL AND GENETIC EVIDENCE FOR TWO INDEPENDENT DISEASES IN PATIENTS CONCURRENTLY POSITIVE FOR JAK2 V617F AND KIT D816V

EHA Library, Juliana Schwaab, 293577

INTERIM ANALYSIS OF A PHASE II TRIAL (HOVON-134) IN MYELOFIBROSIS PATIENTS (PRIMARY, POST-ET OR POST PV-MF) TREATED WITH THE JAK2 INHIBITOR PACRITINIB BEFORE RIC ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Peter te Boekhorst, 293578

CHRONIC NEUTROPHILIC LEUKEMIA AND ATYPICAL CHRONIC MYELOID LEUKEMIA ARE HIGLY OVERLAPPING DISORDERS. RESULTS FROM AN INTERNATIONAL BRITISH-SPANISH STUDY

EHA Library, Gonzalo CARRENO, 293579

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY

EHA Library, Moshe Talpaz, 293580

MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE: CLINICOPATHOLOGICAL CHARACTERISATION AND OUTCOME ANALYSIS

EHA Library, Paul Deschamps, 293581

PHENOTYPIC DIFFERENCES AND PROGNOSTIC IMPACT OF SIGNALING MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Evandro Bezerra, 293582

METFORMIN AND STATINS DO NOT LOWER MYELOFIBROSIS INCIDENS, OVERALL SURVIVAL OR RISK OF LEUKEMIC TRANFORMATION: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Daniel Kristensen, 293583

LONG-TERM SAFETY OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Animesh Pardanani, 293585

SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 293586

TELOMERASE ACTIVITY, TELOMERE LENGTH AND HTERT EXPRESSION CORRELATE WITH CLINICAL OUTCOMES IN HIGHER-RISK MYELOFIBROSIS (MF) RELAPSED/REFRACTORY (R/R) TO JANUS KINASE INHIBITOR TREATED WITH IMETELSTAT

EHA Library, John Mascarenhas, 293587

MYELOABLATIVE FLUDARABINE AND BUSULFAN REGIMEN IN MYELOFIBROSIS: LONG TERM OUTCOMES AND ANALYSIS OF PROGNOSTIC FACTORS

EHA Library, Jacinth Joseph, 293588

KIDNEY DYSFUNCTION IS ASSOCIATED WITH INCREASED THROMBOSIS BUT NOT SEVERE BLEEDING EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: AN ANALYSIS FROM THE GERMAN GSG-MPN BIOREGISTRY

EHA Library, Steffen Koschmieder, 293589

IMETELSTAT TREATMENT RESULTS IN CLINICAL BENEFITS, INCLUDING IMPROVED OVERALL SURVIVAL, IN PATIENTS WITH HIGHER-RISK TRIPLE-NEGATIVE MYELOFIBROSIS RELAPSED/REFRACTORY TO JANUS KINASE INHIBITORS (JAKI)

EHA Library, Jean-Jacques KILADJIAN, 293590

THE WHO SUBCATEGORY 'MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND REARRANGEMENT OF PDGFRA, PDGFRB OR FGFR1, OR PCM1-JAK2' REVISITED IN 74 PATIENTS: LACK OF EOSINOPHILIA AND PRESENCE OF MONOCYTOSIS

EHA Library, Laurenz Steiner, 293591

MOMELOTINIB DOSE-INTENSITY IS MAINTAINED IN JAK INHIBITOR NAÏVE AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS

EHA Library, Vikas Gupta, 293592

USE OF NEXT GENERATION SEQUENCING GENE PANEL FOR IDIOPATHIC ERYTHROCYTOSIS IN A SINGLE CENTRE

EHA Library, Rebekah Williams, 293593

MYSEC-PROGNOSTIC MODEL AND PREVIOUS THROMBOTIC EVENTS PREDICT THE RISK OF THROMBOSIS IN POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY OF THE MYSEC GROUP

EHA Library, Barbara Mora, 293594

HAEMATOLOGICAL MALIGNANCIES IN RELATIVES OF PATIENTS AFFECTED WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniele Vanni, 293595

FAVORABLE OVERALL SURVIVAL WITH IMETELSTAT TREATMENT CORRELATES WITH OTHER CLINICAL BENEFITS IN INTERMEDIATE 2 OR HIGH RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JANUS KINASE INHIBITOR

EHA Library, John Mascarenhas, 293596

MUTATIONAL GENOMIC PROFILE OF TRIPLE-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS USING NEXT-GENERATION SEQUENCING

EHA Library, Sara Duarte, 293597

EARLY ONSET OF SPLEEN AND SYMPTOM RESPONSES WITH FEDRATINIB (FEDR) IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Francesco Passamonti, 293598

PULMONARY HYPERTENSION IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM: A SINGLE CENTER RETROSPECTIVE ANALYSIS OF 225 PATIENTS

EHA Library, Ik-Chan Song, 293599

OUTCOMES OF 99 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (SVT): FIRST REPORT FROM THE UK MASCOT REGISTRY

EHA Library, Hannah Brown, 293600

PATIENT-REPORTED PHYSICAL, EMOTIONAL AND ECONOMIC IMPACT OF MYELOPROLIFERATIVE NEOPLASMS IN AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Guray Saydam, 293601

LONG TERM SAFETY OF MOMELOTINIB IN JAK INHIBITOR NAÏVE AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS

EHA Library, Claire Harrison, 293602

A POPULATION-BASED STUDY OF CHRONIC EOSINOPHILIC LEUKEMIA-NOT OTHERWISE SPECIFIED IN THE UNITED STATES: 2004-2015

EHA Library, Gordon Ruan, 293603

RUXOLITINIB IN PV PATIENTS RESISTANT AND/OR INTOLERANT TO HYDROXYUREA: INTERIM ANALYSIS OF A EUROPEAN MULTI-CENTRIC OBSERVATIONAL STUDY

EHA Library, Peter te Boekhorst, 293604

RUXOLITINIB COMBINED WITH PREDNISONE, THALIDOMIDE AND DANAZOL THERAPY IN MYELOFIBROSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, Zhijian Xiao, 293605

MACHINE-LEARNING TO PREDICT HYDROXYUREA (HU) FAILURE AND INCIDENCE OF THROMBOEMBOLIC EVENTS (TES) WITH HU VS RUXOLITINIB SWITCH THERAPY IN POLYCYTHEMIA VERA PATIENTS

EHA Library, Srdan Verstovsek, 293606

CLINICAL-PATHOLOGICAL FEATURES OF TRIPLE-NEGATIVE ESSENTIAL THROMBOCHYTEMIA

EHA Library, Daniele Cattaneo, 293607

USE OF BIOSIMILAR ERYTHROPOIESIS STIMULANTING AGENTS FOR ANEMIA IN MYELOFIBROSIS: A MULTICENTER REAL-LIFE EXPERIENCE ON 40 PATIENTS

EHA Library, Elena Inzoli, 293608

REAL-WORLD SURVIVAL IN ELDERLY PATIENTS WITH MYELOFIBROSIS IN THE UNITED STATES: PRE- VS POST-RUXOLITINIB APPROVAL

EHA Library, Srdan Verstovsek, 293609

PREGNANCY OUTCOMES IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RECENT, EXTENDED RETROSPECTIVE ANALYSIS

EHA Library, Bozena Sokolowska, 293610

USE OF NEXT-GENERATION SEQUENCING TO IDENTIFY MYELOID MUTATIONS ASSOCIATED WITH THROMBOTIC RISK IN PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Ruth Stuckey, 293611

TREATMENT AND DISEASE MANAGEMENT PRACTICES IN PATIENTS WITH MPNS IN 6 COUNTRIES: AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Cheng-Shyong Chang, 293612

REAL-WORLD SURVIVAL IN ELDERLY PATIENTS WITH MYELOFIBROSIS IN THE UNITED STATES: RUXOLITINIB EXPOSED VS UNEXPOSED

EHA Library, Srdan Verstovsek, 293613

IMPACT OF PLATELET COUNT ON THROMBOTIC RISK IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA WITH NORMAL LEUKOCYTE COUNT

EHA Library, Veronika Buxhofer-Ausch, 293614

RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE ANALYSIS OF REAL-WORLD PATIENTS IN ENGLAND, NORTHERN IRELAND AND WALES

EHA Library, James Russell, 293615

SPLEEN STIFFNESS MEASUREMENT BY USING SHEAR-WAVE ELASTOGRAPHY AS A PREDICTOR OF PROGRESSION TO SECONDARY MYELOFIBROSIS

EHA Library, Omer Ekinci, 293616

SECOND CANCER IN MYELOFIBROSIS TREATED WITH RUXOLITINIB: A 'REAL-LIFE' RETROSPECTIVE MULTICENTER EXSPERIENCE OF THE RETE EMATOLOGICA PUGLIESE (REP)

EHA Library, Erminia Rinaldi, 293617

IMPACT OF INTERIM PET ON HODGKIN LYMPHOMA TREATMENT OUTCOMES AND SURVIVAL IN CLINICAL PRACTICE.

EHA Library, Serena Zheng, 293618

DOSE-INTENSIFICATION IN EARLY UNFAVORABLE HODGKIN LYMPHOMA: LONG-TERM FOLLOW UP OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL

EHA Library, Bastian Von Tresckow, 293619

NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY OR TARGETED THERAPY IN THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Liudmila Fedorova, 293620

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN REAL CLINICAL PRACTICE: PROLONGED FOLLOW UP AND PROGNOSTIC FACTORS ANALYSIS

EHA Library, Lepik Kirill, 293621

THE COMBINED PROGNOSTIC ROLE OF INTERIM 18FDG-PET AND TARC IN HODGKIN LYMPHOMA

EHA Library, Laszlo Pinczes, 293622

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 4-YEAR UPDATE OF THE ECHELON-1 STUDY

EHA Library, Marco Picardi, 293624

EA(50)COPP-14 ± RADIOTHERAPY IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH ADVANCED STAGES OF CLASSICAL HODGKIN LYMPHOMA: RESULTS OF THE MODIFIED PROTOCOL «HLMOSCOW 1-3»

EHA Library, Gayane Tumyan, 293626

CARDIOVASCULAR DISEASES IN HODGKIN'S LYMPHOMA SURVIVORS: A SINGLE CENTER EXPERIENCE

EHA Library, Maria Pina Simula, 293627

OBJECTIVE RESPONSE RATES AND QUALITY OF LIFE CHANGES IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RR HL) RECEIVING BRENTUXIMAB VEDOTIN AS >2 LINE OF TREATMENT IN THE REAL WORLD SETTING

EHA Library, Tatyana Ionova, 293628

PARANEOPLASTIC CEREBELLAR DEGENERATION ASSOCIATED WITH HODGKIN LYMPHOMA : A FRENCH RETROSPECTIVE COHORT

EHA Library, Kentin Queru, 293629

PROGNOSTIC VALUE OF THE FUNCTIONAL PARAMETERS: TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TOTAL LESION GLYCOLYSIS (TLG) AT BASELINE [18F]FDG-PET/CT IN HODGKIN LYMPHOMA

EHA Library, Francisca Hernandez Mohedo, 293630

AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY TO DESCRIBE TREATMENT PATHWAYS AND OUTCOMES FOR CLASSICAL HODGKIN LYMPHOMA IN EAST ASIA: INTERIM RESULTS

EHA Library, Tae Min Kim, 293631

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND CLINICAL OUTCOMES IN THE FRONTLINE TREATMENT OF ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA IN ITALY, SPAIN, AND ISRAEL

EHA Library, Abraham Avigdor, 293632

CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN CHILDREN AND YOUNG-ADULTS WITH HODGKIN'S LYMPHOMA: A KPHOG LYMPHOMA WORKING-PARTY, MULTICENTER, RETROSPECTIVE STUDY

EHA Library, Jae Min Lee, 293633

IMPACT OF NIVOLUMAB ON OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Philippe Armand, 293634

REAL-LIFE VALIDATION OF A SIMPLIFIED INTERNATIONAL PROGNOSTIC SCORE VERSION (IPS-3) IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA

EHA Library, Theodoros P. Vassilakopoulos, 293635

SECONDARY MALIGNANCIES IN HODGKIN LYMPHOMA SURVIVORS: A SINGLE CENTER EXPERIENCE

EHA Library, Maria Pina Simula, 293636

TREATMENT PATHWAYS AND CLINICAL OUTCOMES OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN LATIN AMERICA: INTERIM RESULTS FROM AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY

EHA Library, Amado Karduss Urueta, 293637

THE HODGKIN LYMPHOMA INTERNATIONAL STUDY FOR INDIVIDUAL CARE (HOLISTIC): A MULTI-NATIONAL COLLABORATIVE TO ENHANCE DECISION MAKING FOR PEDIATRIC AND ADULT HODGKIN LYMPHOMA (HL)

EHA Library, Andrew Evens, 293638

THE EFFECTS OF THYROID DYSFUNCTION ON BONE REMODELING IN PATIENTS WITH HODGKIN'S LYMPHOMA

EHA Library, Mariia Voytko, 293639

TREATMENT PATTERNS AND EFFECTIVENESS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA WHO RECEIVED AUTOLOGOUS AND/OR ALLOGENIC STEM CELL TRANSPLANTATION

EHA Library, Monika Raut, 293640

BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN'S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE

EHA Library, Burhan Ferhanoglu, 293641

FINAL ANALYSIS OF AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA.

EHA Library, DAVID SIBON, 293642

PROGNOSTIC ROLE OF END OF TREATMENT PET/CT DEAUVILLE SCORE IN HODGKIN LYMPHOMA.

EHA Library, Maria Lucia De Luca, 293643

BRENTUXIMAB VEDOTIN THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ALLOGENEIC STEM CELLS TRANSPLANTATION: SINGLE CENTER EXPERIENCE

EHA Library, Anastasiya Beynarovich, 293644

COMPARATIVE ANALYSIS OF THE VARIOUS THERAPEUTIC STRATEGIES USED IN HODGKIN'S LYMPHOMA WITH A MASSIVE MEDIASTINAL BULKY: BEACOPP VS ABVD AND RADIOTHERAPY TYPE COMPLETE MANTLE VERSUS IFRT

EHA Library, Talbi Faiza, 293645

THERAPEUTIC CHALLENGES IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA – A SINGLE INSTITUTION LONG-STANDING EXPERIENCE

EHA Library, Krasen Venkov, 293646

FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE GALLIUM STUDY: PROGNOSTIC VALUE OF PET-CT STATUS AFTER LONG-TERM FOLLOW-UP

EHA Library, Judith Trotman, 293647

CONDITIONAL RELATIVE SURVIVAL AMONG PATIENTS WITH FOLLICULAR LYMPHOMA IN THE NETHERLANDS: A POPULATION-BASED STUDY, 1989-2017

EHA Library, Manette Dinnessen, 293648

FOCUS ON PATIENTS WITH TP53 DISRUPTION IN THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL: UNIFORM POOR OUTCOME, REGARDLESS OF BASELINE PREDICTORS, MRD STATUS AND LENALIDOMIDE MAINTENANCE

EHA Library, Simone Ferrero, 293649

MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

EHA Library, Mathias Rummel, 293650

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + VENETOCLAX (VEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

EHA Library, Sam Yuen, 293651

CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA PATIENTS WITH HIGH RISK BIOLOGY (HIGH KI-67, BLASTIC MCL, OR HIGH P53 EXPRESSION)

EHA Library, Martin Dreyling, 293652

IINVOLVED FIELD RADIATION THERAPY (IFRT) ± LOW-DOSE TOTAL BODY IRRADIATION (TBI) FOR LOCALIZED INDOLENT B-NHL: FINAL ANALYSIS OF RANDOMIZED EORTC TRIAL 20971-22997

EHA Library, Igor Aurer, 293653

PHASE 1/2 STUDY OF SINGLE-AGENT ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

EHA Library, Alessandra Tedeschi, 293654

CONCURRENT TP53 AND CDKN2A GENE ABERRATIONS IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA CORRELATE WITH CHEMORESISTANCE AND CALL FOR INNOVATIVE UPFRONT THERAPY

EHA Library, Diana Malarikova, 293655

TREATMENT AND SURVIVAL IN PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA: A POPULATION-BASED STUDY

EHA Library, Lei Fan, 293656

THREE-YEAR FOLLOW-UP OF TREATMENT-NAÏVE AND PREVIOUSLY TREATED PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) RECEIVING SINGLE AGENT ZANUBRUTINIB

EHA Library, Stephen Opat, 293657

OUTCOMES OF RELAPSED/REFRACTORY MCL PATIENTS TREATED WITH ZANUBRUTINIB MONOTHERAPY IN THE SECOND LINE AND IN LATER LINES: A POOLED ANALYSIS FROM 2 STUDIES

EHA Library, Keshu Zhou, 293658

SUSTAINED CLINICAL BENEFIT OF OBINUTUZUMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: UPDATED RESULTS FROM THE GALLIUM STUDY

EHA Library, William Townsend, 293659

FEASIBILITY OF COMBINING THE PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITOR COPANLISIB WITH RITUXIMAB (R)-BASED IMMUNOCHEMOTHERAPY IN PATIENTS (PTS) WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (INHL)

EHA Library, Pier Luigi Zinzani, 293660

INTERIM RESULTS OF R-BAC/R-C FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MANTLE CELL LYMPHOMA WITHOUT TP53 MUTATION

EHA Library, Daria Koroleva, 293661

SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX INPREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS.

EHA Library, Anastasios Stathis, 293662

THE PI3KΔ INHIBITOR ME-401 IS WELL-TOLERATED ON INTERMITTENT SCHEDULE AND PRODUCES A HIGH-RATE OF DURABLE RESPONSES IN RELAPSED/REFRACTORY (R/R) INDOLENT B-CELL MALIGNANCIES

EHA Library, JM Pagel, 293663

PATIENTS WITH GRADE 3B FOLLICULAR LYMPHOMA EXPERIENCE SUPERIOR OUTCOMES COMPARED WITH DIFFUSE LARGE CELL LYMPHOMA, BUT SHOW A CONTINUOUS PATTERN OF RELAPSE

EHA Library, Allison Barraclough, 293664

CORRELATION OF THE MCL35 SCORE AND GENE MUTATIONS WITH OUTCOME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN THE MCL3001 RAY TRIAL

EHA Library, Ciara L Freeman, 293665

IBRUTINIB AS SECOND-LINE THERAPY IS WELL TOLERATED AND EFFICACIOUS IN FRAIL PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA WHO ARE UNSUITABLE FOR STANDARD FRONT-LINE THERAPIES

EHA Library, Sophie Johns, 293666

CLARITHROMYCIN AND LENALIDOMIDE COMBINATION: A FULL ORAL REGIMEN FOR RELAPSED/REFRACTORY MALT LYMPHOMA PATIENTS. RESULTS OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG40/CLEO TRIAL

EHA Library, Andrés José María Ferreri, 293667

END-OF-TREATMENT 18[F]-FDG PET CAN PREDICT PROGRESSION-FREE SURVIVAL IN PATIENTS UNDERGOING BENDAMUSTINE-RITUXIMAB FOR FIRST RELAPSED/RECURRENT FOLLICULAR LYMPHOMA: A PROSPECTIVE W-JHS NHL01 TRIAL

EHA Library, Shinya Rai, 293668

UPDATED RESULTS OF THE ASPEN TRIAL FROM A COHORT OF PATIENTS WITH MYD88 WILD-TYPE WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Meletios Dimopoulos, 293669

THE INTERVAL BETWEEN FRONTLINE TREATMENT AND SECOND RELAPSE (PFS2) PREDICTS SURVIVAL FROM SECOND RELAPSE (SFR2) IN FOLLICULAR LYMPHOMA PATIENTS

EHA Library, Pablo Mozas, 293670

CAN 18F-FDG PET/CT OVERCOME ENDOSCOPY IN THE STAGING OF GASTROINTESTINAL INVOLVEMENT IN MANTLE CELL LYMPHOMA? A RETROSPECTIVE MULTI-CENTER COHORT ANALYSIS.

EHA Library, Tetiana Skrypets, 293671

OUTCOMES BASED ON INDICATION FOR TREATMENT AND CHOICE OF FRONTLINE REGIMEN IN WALDENSTRÖM'S MACROGLOBULINAEMIA

EHA Library, Oliver Tomkins, 293672

CLINICAL MOLECULAR DIAGNOSTICS LABORATORY VALIDATION OF THE MCL35 GENE EXPRESSION PROFILING ASSAY FOR MOLECULAR RISK STRATIFICATION OF MANTLE CELL LYMPHOMA

EHA Library, Ryan S. Robetorye, 293673

IDELALISIB IMMUNE-RELATED TOXICITY PREDICTS IMPROVED TREATMENT RESPONSE FOR INDOLENT NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Nina Wagner-Johnston, 293674

A LOW LYMPHOCYTE TO MONOCYTE RATIO (LMR) IS AN INDEPENDENT PREDICTOR OF POORER SURVIVAL AND HIGHER RISK OF HISTOLOGICAL TRANSFORMATION IN PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Pablo Mozas, 293675

CLINICAL CHARACTERISTICS AND OUTCOMES OF PRIMARY VERSUS SECONDARY GASTROINTESTINAL MANTLE CELL LYMPHOMA

EHA Library, Aung Tun, 293676

LRPAP1-AUTOANTIBODIES IN MANTLE CELL LYMPHOMA APPEAR TO BE ASSOCIATED WITH AN IMPROVED OUTCOME

EHA Library, Lorenz Thurner, 293677

ALTERNATIVE ANTI-CD20 ANTIBODY VERSUS DESENSITIZATION FOR LYMPHOMA PATIENTS WITH DRUG HYPERSENSITIVITY REACTIONS REQUIRING DISCONTINUATION OF RITUXIMAB, OBINUTUZUMAB OR OFATUMUMAB.

EHA Library, Paola Ghione, 293678